Guide
EU GMP for Medicinal Cannabis: From Cultivation to QP Release
Medicinal cannabis placed on the EU market is a herbal medicinal product or an active pharmaceutical ingredient (API) and must be manufactured under EU GMP — EudraLex Volume 4 Part I, Part II (active substances), Annex 7 (herbal medicinal products), Annex 8 (sampling), and where applicable Annex 1 (sterile manufacturing). A Qualified Person (QP) certifies each batch for release. The pathway is longer and more expensive than the US state-licensed model, but the resulting export status (Germany, Israel, Australia, UK, several Latin American markets) is the commercial reason most multinational producers run an EU-GMP site. This guide walks the regulatory map, the recurring inspection findings, and a practical path to a defensible EU-GMP cannabis programme.
Start free trial Free trial, no credit card, onboard in days, not months.
The regulatory map: Part I, Part II, Annex 7, Annex 1
Cultivation and primary processing of medicinal cannabis API typically run under Annex 7 (herbal medicinal products) overlaid on Part II (active substances). Extraction, isolation and purification of cannabinoid API run under Part II. Formulation, filling and packaging of finished medicinal product run under Part I. Sterile dosage forms (rare in cannabis, but emerging for inhalation) trigger Annex 1 in full, including the contamination control strategy and the 2022 revision's gradeline expectations. The recurring scoping mistake is to treat the entire site under Part I and miss the Annex 7 sampling and characterisation expectations on the upstream botanical.
The Qualified Person and batch certification
Article 51 of Directive 2001/83/EC places personal regulatory liability on a QP to certify that each batch of medicinal product has been manufactured and tested in accordance with the marketing authorisation and EU GMP before release. The QP's certification is not a sign-off on a summary; it is a personal attestation reviewed by the EU inspectorate at every audit. A QP relying on a CoA summary without the underlying batch record, in-process controls, deviation file and OOS investigation cannot defend the certification when it is questioned.
Cultivation under Annex 7 and the agricultural-to-GMP transition
Annex 7 explicitly addresses Good Agricultural and Collection Practice (GACP) for the cultivation step and the transition to GMP for primary processing. The cultivation site must operate under GACP with controls on starting material identity, growing conditions, pest management, harvest, drying and storage; the GMP boundary begins at the controlled storage of dried herbal substance. Inspections find the boundary handled either as a sharp transition (clear documented handover) or as an undocumented blur — the latter is a recurring critical finding.
Cannabinoid profile, characterisation and the variability problem
Medicinal cannabis APIs are characterised by cannabinoid profile (THC, CBD, minor cannabinoids, terpenes), not by a single chemical entity. Marketing authorisations and pharmacopeial monographs increasingly require profile-level specifications, not headline THC/CBD. Producers running a programme designed around headline potency miss the trend analysis on minor cannabinoid drift that auditors now ask about, and miss the link between cultivar genetics, growing condition variability and finished-product variability.
A 60-day readiness path
Days 1–10: scoping audit — confirm Part I, Part II, Annex 7 and (if applicable) Annex 1 boundaries are documented and the correct record set is in use at each step. Days 11–25: GACP-to-GMP handover review; document the transition explicitly. Days 26–40: QP dossier rehearsal — pick three recent batches and walk the full file the QP sees at certification. Days 41–55: cannabinoid profile trend analysis at cultivar/harvest/finished-product level; close characterisation gaps. Days 56–60: full EU-GMP self-inspection rehearsal with QP-led closing meeting.
Where this lives in V5 Ultimate
The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.
Modules that do the work
Industries this hits hardest
Frequently asked
Can I export US-state cannabis to the EU?
Only via an EU-GMP-certified manufacturing chain. State-licensed THC cannabis from a non-EU-GMP site cannot be placed on the EU medicinal market regardless of state-level licensure.
Is GACP a separate inspection?
GACP itself is not an EU-GMP certification, but the GACP step is inspected by the same competent authority as part of the EU-GMP scope where Annex 7 applies. A weak GACP file undermines the GMP certificate.
Does Annex 1 apply to vaporiser/inhalation products?
Yes — any sterile dosage form, including dry-powder inhalers or sterile pulmonary delivery, falls under Annex 1 in full. The 2022 revision's contamination control strategy is in scope.
Is the EU monograph for cannabis flos finalised?
As of mid-2026, Ph. Eur. monographs for cannabis flos, cannabis extracts and individual cannabinoid APIs are at various stages of finalisation; check the current edition and pharmeuropa drafts before relying on a specification. Several national pharmacopoeias (DAB, BP) carry interim monographs.
See it on your shop floor.
Free trial, no credit card, onboard in days, not months.